Common Migraine Drug Shows Promise in Reducing Stroke Risk for Women
New research reveals propranolol, a widely-used medication for migraines and high blood pressure, may significantly reduce ischemic stroke risk in women with migraines, particularly those without aura, highlighting an important advancement in women's cardiovascular health management.
A large-scale analysis of over 3 million medical records suggests that propranolol, a common beta blocker used to treat migraines and high blood pressure, could reduce the risk of ischemic stroke in women by up to 52%, according to preliminary research to be presented at the American Stroke Association's International Stroke Conference 2025.
The findings are particularly significant for women's health, as migraines affect women three times more frequently than men and are an often-overlooked risk factor for cardiovascular issues. The study found that women taking propranolol showed a 39-52% lower risk of developing ischemic stroke, with the protective effect being strongest in women who experience migraines without aura. Notably, the medication showed no similar protective effects in men.
This research has important implications for healthcare equity, as migraine disproportionately affects women from historically under-resourced communities. 'Many women suffer from migraines, and it's important to note that propranolol may be beneficial for these women, particularly those who experience migraine without aura,' said lead study author Mulubrhan Mogos, Ph.D., from Vanderbilt University School of Nursing.
The study's findings could reshape treatment approaches for women with frequent migraines, offering a cost-effective option that provides dual benefits of migraine prevention and stroke risk reduction. While the research is preliminary and requires further validation through prospective studies, it represents a potentially significant advancement in understanding how to better protect women from stroke risk, particularly those who suffer from migraines without aura.